Scott William Drake Sells 38,641 Shares of AtriCure, Inc. (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Scott William Drake sold 38,641 shares of the firm’s stock in a transaction that occurred on Friday, May 7th. The shares were sold at an average price of $77.90, for a total value of $3,010,133.90. Following the completion of the sale, the director now directly owns 79,677 shares of the company’s stock, valued at approximately $6,206,838.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Scott William Drake also recently made the following trade(s):

  • On Monday, May 10th, Scott William Drake sold 4,631 shares of AtriCure stock. The shares were sold at an average price of $76.52, for a total value of $354,364.12.

ATRC stock opened at $70.58 on Thursday. The stock’s fifty day simple moving average is $68.73 and its two-hundred day simple moving average is $57.50. The company has a current ratio of 6.62, a quick ratio of 5.85 and a debt-to-equity ratio of 0.15. AtriCure, Inc. has a 1-year low of $34.04 and a 1-year high of $80.44. The stock has a market cap of $3.22 billion, a P/E ratio of -61.37 and a beta of 1.13.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Monday, April 26th. The medical device company reported ($0.38) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.38). AtriCure had a negative return on equity of 14.83% and a negative net margin of 21.74%. As a group, analysts forecast that AtriCure, Inc. will post -1.09 earnings per share for the current fiscal year.

Several research analysts recently issued reports on ATRC shares. Piper Sandler lifted their target price on AtriCure from $70.00 to $85.00 in a research report on Thursday, April 29th. BTIG Research lifted their target price on AtriCure from $69.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, April 28th. Oppenheimer lifted their target price on AtriCure from $65.00 to $75.00 and gave the company an “outperform” rating in a research report on Tuesday, May 4th. Canaccord Genuity lifted their target price on AtriCure from $77.00 to $102.00 and gave the company a “buy” rating in a research report on Tuesday, May 4th. Finally, SVB Leerink reaffirmed a “buy” rating on shares of AtriCure in a research report on Thursday, April 29th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $78.50.

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in shares of AtriCure by 12.4% in the first quarter. Geode Capital Management LLC now owns 777,378 shares of the medical device company’s stock valued at $50,933,000 after buying an additional 85,827 shares during the period. Prudential Financial Inc. raised its stake in shares of AtriCure by 15.0% in the first quarter. Prudential Financial Inc. now owns 5,676 shares of the medical device company’s stock valued at $372,000 after buying an additional 742 shares during the period. Advisors Capital Management LLC bought a new stake in shares of AtriCure in the first quarter valued at $1,284,000. JPMorgan Chase & Co. raised its stake in shares of AtriCure by 7.8% in the first quarter. JPMorgan Chase & Co. now owns 60,584 shares of the medical device company’s stock valued at $3,969,000 after buying an additional 4,366 shares during the period. Finally, Sei Investments Co. raised its stake in shares of AtriCure by 57.0% in the first quarter. Sei Investments Co. now owns 167,618 shares of the medical device company’s stock valued at $10,937,000 after buying an additional 60,838 shares during the period. Hedge funds and other institutional investors own 94.70% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Further Reading: What is the Fibonacci sequence?

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.